1. South Korea Stocks

  2. •

    Health technology

  3. •

    Medical specialties
BioPlus Co. Ltd.

BioPlus Co. Ltd.

KKRX:099430
3,480.00
KRW
-105.00
(-2.93%)
309.90EPS
18.36P/E
256.93BMarket Cap
Nov 18Next Earn
BioPlus Co. Ltd.
KRX:099430
(Korea Stock Exchange)

Recent

price

3,480.00

P/E

ratio

18.36

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
148.65
473.14
705.24
488.44
722.28
976.76
1,131.49
1,168.53
1,532.97
1,628.57
Revenue per Share
16
99.75
233
194.5
207.02
364
445
249
253
227.42
Basic EPS, GAAP
-11.85
103.44
-64.27
179.35
-38.71
114.78
-96.23
-1,308.36
-559.75
-94.83
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
90.28
132.77
321.46
513.73
1,404.18
1,955.18
2,235.05
2,355.56
2,841.1
2,899.49
Book Value per Share
48.74
99.62
285.02
478.58
1,356.89
1,910.1
2,116.45
2,218.33
2,698.82
2,754.51
Tangible Book Value per Share
23
23
24
50
52
58
57
57
59
61
Basic Weighted Avg Shares
3,489
11,038
17,021
24,367
37,418
56,719
65,043
66,410
90,896
99,152
Sales/Revenue/Turnover
11.39
36
40.47
50.59
48.71
44.56
43.09
35.64
16.51
17.89
Operating Margin (%)
391
512
867
1,010
1,298
1,887
2,490
3,270
4,063
4,512
Depreciation Expense
376
2,327
5,623
9,703
10,725
21,137
25,581
14,151
15,001
13,846
Net Income, GAAP
- -
19.38
16.31
20.04
24.67
24.62
16.24
0.87
- -
- -
Effective Tax Rate (%)
10.76
21.08
33.04
39.82
28.66
37.27
39.33
21.31
16.5
13.96
Profit Margin (%)
2,640
7,871
7,797
16,405
46,917
96,582
86,372
-35,508
-12,522
-3,757
Working Capital
- -
- -
46
38
369
282
1,988
2,746
4,522
14,001
LT Debt
5,012
7,371
17,846
28,520
80,525
114,961
138,061
147,740
194,980
200,329
Total Equity
- -
50.61
45.97
39.52
24.1
18.95
18.05
13.76
- -
- -
Return on Invested Capital (%)
- -
36.37
44.91
38.68
19.4
21.74
18.56
6.43
- -
- -
Return on Capital (%)
- -
37.59
44.6
41.85
20.01
22.02
21.22
10.83
9.73
8.32
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
55,539
49,679
51,652
LT Borrowings
4,295
14,164
13,570
LT Finance Leases
227
204
432
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
62
62
62
Market Capitalization
309,549
300,625
256,931

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
64,783
71,117
68,295
Cash, Cash Equivalents & STI
27,182
30,745
29,346
Accounts Receivable, Net
11,421
12,791
12,532
Inventories
15,643
16,214
16,422
Total Current Liabilities
77,305
75,845
72,053
Payables & Accruals
- -
- -
- -
ST Debt
55,539
49,679
51,652
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
56.83%
31.97%
Free Cash Flow
- -
90.21%
-55.36%
Net Income, GAAP
- -
17.99%
6.01%
Sales/Revenue/Turnover
- -
31.76%
36.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,613
11,289
16,417
29,091
66,410
2025
22,982
20,674
24,056
23,184
90,896
2026
26,510
25,402
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
39
98
58
53.85
249
2025
133
37
52.75
32.55
253
2026
109.12
33.05
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Bio Plus Co., Ltd (099430.KQ) engages in the research, development, production, and sale of bio products, primarily hyaluronic acid-based biomaterials for medical devices and aesthetics in South Korea. The company offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names; medical products including InterBlock, an absorbable anti-adhesion barrier, Synofil, a synovial fluid replacement, and Blad-Care, a solution to improve cystitis symptoms; mesotherapy products such as Kiara Reju skin rejuvenation solutions, Slim Slimmer lipolysis solution, LumiDew whitening solution, JuveniHill anti-wrinkle solution, BelloHa and BellaChe hair scalp care, treatment, and nutrition solutions; and cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. Founded in 2003 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, Bio Plus operates in the surgical and medical instruments industry, targeting aesthetic clinics, medical professionals, and cosmeceutical markets primarily in Asia with exports leveraging its MDM® technology for hyaluronic acid applications. In recent developments, the company launched HUGRO, a patented growth factor-based cell booster brand featuring products like an eyelash serum and peptide haircare in collaboration with GL Earth for December market entry, while advancing its new Bio-Complex plant in Eumseong toward GMP certification to expand production of botulinum toxin, obesity treatments, and next-generation diet injections; it also authorized a share buyback plan in June 2024 and pursues partnerships such as with Orabio for improved botulinum toxin development.